Maravai LifeSciences Holdings, Inc. (MRVI) P/E Ratio History
Deep ValueTrading at -5.8x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2020–2023
Loading P/E history...
P/E Ratio Analysis
As of June 23, 2026, Maravai LifeSciences Holdings, Inc. (MRVI) trades at a price-to-earnings ratio of -5.8x, with a stock price of $5.25 and trailing twelve-month earnings per share of $-0.71.
The current P/E is 131% below its 5-year average of 18.7x. Over the past five years, MRVI's P/E has ranged from a low of 3.7x to a high of 36.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, MRVI trades at a 126% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
Relative to the broader market, MRVI trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MRVI DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MRVI Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
MRVI P/E vs Peers
Life Science Tools and Reagents peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $38B | 122.9 | - | +207%Best | |
| $25B | 29.6Lowest | 7.02Best | +171% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
MRVI Historical P/E Data (2020–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q3 | Sep 30 2023 | $10.00 | $0.55 | 18.1x | -3% |
| FY2023 Q2 | Jun 30 2023 | $12.43 | $1.36 | 9.1x | -51% |
| FY2023 Q1 | Mar 31 2023 | $14.01 | $2.69 | 5.2x | -72% |
| FY2022 Q4 | Dec 31 2022 | $14.31 | $3.90 | 3.7x | -80% |
| FY2022 Q3 | Sep 30 2022 | $25.53 | $3.66 | 7.0x | -63% |
| FY2022 Q2 | - | $28.41 | $3.34 | 8.5x | -54% |
| FY2022 Q1 | - | $35.27 | $2.50 | 14.1x | -24% |
| FY2021 Q4 | Dec 31 2021 | $41.90 | $1.54 | 27.2x | +46% |
| FY2021 Q3 | - | $49.08 | $1.34 | 36.6x | +96% |
| FY2021 Q2 | Jun 30 2021 | $41.73 | $1.34 | 31.1x | +67% |
| FY2021 Q1 | Mar 31 2021 | $35.64 | $1.16 | 30.7x | +65% |
| FY2020 Q4 | - | $28.05 | $0.86 | 32.5x | +74% |
Average P/E for displayed period: 18.7x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MRVI — Frequently Asked Questions
Quick answers to the most common questions about buying MRVI stock.
What is MRVI's P/E ratio?
Maravai LifeSciences Holdings, Inc. (MRVI) trailing twelve-month P/E ratio is -5.8x, based on TTM diluted EPS of $-0.71. The 5-year average P/E is 18.7x and the historical range spans 3.7x to 36.6x.
Is MRVI stock overvalued or undervalued?
MRVI trades at -5.8x P/E, below its 5-year average of 18.7x. At the 0th percentile of its historical range (3.7x–36.6x), the stock is priced at a discount to its own history.
Is MRVI stock expensive?
No, MRVI is not expensive on a historical basis. The current P/E of -5.8x is below the 5-year average of 18.7x and sits at the 0th percentile of its valuation range.
What is MRVI's historical P/E range?
Over the past 5 years, MRVI's P/E ratio has ranged from 3.7x to 36.6x, with a median of 18.1x and an average of 18.7x. The current P/E of -5.8x places the stock at the 0th percentile of this range. Full historical data spans 2020–2023.
How does MRVI's P/E compare to the S&P 500?
MRVI trades at -5.8x P/E versus the S&P 500 median of 24.3x. The 124% discount to the market suggests lower growth expectations or perceived higher risk.
How does MRVI's valuation compare to Healthcare peers?
Maravai LifeSciences Holdings, Inc. P/E of -5.8x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is MRVI's PEG ratio?
MRVI PEG ratio is N/A, based on a P/E of -5.8x and EPS growth of 13.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is MRVI's earnings yield?
MRVI earnings yield is N/A, the inverse of its -5.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.